Genetic Technologies Limited (ADR)  

(Public, NASDAQ:GENE)   Watch this stock  
Find more results for Mark Ostrowski
+0.01 (0.49%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.00 - 2.10
52 week 1.62 - 11.00
Open 2.09
Vol / Avg. 38,196.00/168,642.00
Mkt cap 24.63M
P/E     -
Div/yield     -
EPS -1.03
Shares 1.71B
Beta 1.04
Inst. own 0%
Feb 29, 2016
Interim 2016 Genetic Technologies Ltd Earnings Release (Estimated) Add to calendar
Jan 27, 2016
Genetic Technologies Ltd KPI Quarterly Report - December 2015
Nov 24, 2015
Genetic Technologies Ltd Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin -523.68% -437.90%
Operating margin -523.68% -437.90%
EBITD margin - -462.62%
Return on average assets -65.66% -64.19%
Return on average equity -82.40% -84.77%
Employees 64 -
CDP Score - -


60-66 Hanover St
Fitzroy, VIC 3065
+61-3-94151135 (Phone)
+61-3-84127040 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Genetic Technologies Limited is a molecular diagnostics company. The Company offers predictive testing and assessment tools to help physicians manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment specialists, such as breast surgeons. The Company operates in Australia, the United States and Switzerland. The Company's subsidiaries include Genetic Technologies Corporation Pty. Ltd. and Phenogen Sciences Inc. The Company has launched the BREVAGen test across the United States through its subsidiary, Phenogen Sciences Inc.

Officers and directors

Eutillio Buccilli Chief Executive Officer, Executive Director
Bio & Compensation  - Reuters
Kevin Fischer Chief Financial Officer, Company Secretary
Bio & Compensation  - Reuters
Mark Ostrowski President of Phenogen Sciences Inc
Age: 50
Bio & Compensation  - Reuters
Richard Allman Ph.D Scientific Director
Age: 53
Bio & Compensation  - Reuters
M. Luisa Ashdown Director of Global Licensing and Intellectual Property
Age: 57
Bio & Compensation  - Reuters
Diana Newport Quality and Business Operations Director
Age: 56
Bio & Compensation  - Reuters
Malcolm Roy Brandon Ph.D. Non-Executive Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Grahame James Leonard Director
Bio & Compensation  - Reuters
Paul Alexander Kasian Non-Executive Director
Bio & Compensation  - Reuters
Lindsay Peter Peter Wakefield Non-Executive Independent Director
Bio & Compensation  - Reuters